Significant events during the first quarter 2023

• Nanexa AB announced positive outcome in the first preclinical study with NEX-22. In a one-month study in rats, single doses of two different PharmaShell® formulations were studied in different doses. The results show a controlled release of liraglutide, with plasma exposure over 28 days for NEX-22, compared to around 2 days for a formulation with liraglutide without the PharmaShell coating.

Significant events after the end of the period

• No significant events after the end of the quarter.

Summary of the reporting period 1 January – 31 March 2023

• Turnover amounted to: TSEK 8,173 (298)
• Operating profit (EBIT) amounted to: TSEK -8,703 (-12,331)
• Profit after tax amounted to: TSEK -8,603 (-12,370)
• Earnings per share amounted to: SEK -0.14 (-0.24)
• Cash flow for the period amounted to: TSEK -20,682 (-17,934)
• Cash and cash equivalents at end of period: TSEK 60,500 (87,726)

Figures in brackets refer to the corresponding period in the previous year.

The entire report is available on the company’s website: https://nanexa.com/en/financial-reports/ .

Report comment, 4 May at 3:00pm CET
A live commentary with CFO Björn Svanström will take place on May 4 at 3:00pm via Infront Direkt Studios and viewers will have the opportunity to ask questions via chat.

The webcast is held in Swedish and can be viewed via this link .
The report comment will also be published on Nanexa’s website afterwards.